Peroxisomal fatty acid metabolism, peroxisomal proliferator-activated receptors and non-alcoholic fatty liver disease

Journal of Gastroenterology and Hepatology (Australia)

Volumn 19, Issue 12, 2004, Pages 1335-1337

  MacDonald, Graeme A ^a,b   Prins, Johannes B ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; CARBON DIOXIDE; HYDROGEN PEROXIDE; LIVER ENZYME; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

EDITORIAL; ENDOPLASMIC RETICULUM; FATTY ACID METABOLISM; FATTY ACID OXIDATION; FATTY LIVER; INSULIN RESISTANCE; LIPID STORAGE; NONALCOHOLIC FATTY LIVER; OBESITY; PREVALENCE; PRIORITY JOURNAL; TISSUE SPECIFICITY;

EID: 11144226736     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2004.03562.x     Document Type: Editorial

References (28)

1. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-57.
2. Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J. Gastroenterol. Hepatol. 2003; 18: 124-38.
3. Chitturi S, Abeygunasekera S, Farrell GC et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002; 35: 373-9.
4. Shulman GI. Cellular mechanisms of insulin resistance. J. Clin. Invest. 2000; 106: 171-6.
5. Yeon J, Choi K, Baik S et al. Reduced expression of peroxisome proliferator-activated receptor alpha may have an important role in the development of non-alocholic fatty liver disease. J. Gastroenterol. Hepatol. 2004; 19: 799-804.
6. Rasmussen BB, Wolfe RR. Regulation of fatty acid oxidation in skeletal muscle. Annu. Rev. Nutr. 1999; 19: 463-84.
7. Garrett R, Grisham C. β-oxidation of fatty acids. In: Garrett R, Grisham C, eds. Biochemistry. Fort Worth: Saunders College Publishing, 1999; 775-801.
8. Kunau WH, Dommes V, Schulz H. Beta-oxidation of fatty acids in mitochondria, peroxisomes, and bacteria: a century of continued progress. Prog. Lipid Res. 1995; 34: 267-342.
9. Kim JJ, Battaile KP. Burning fat: the structural basis of fatty acid beta-oxidation. Curr. Opin. Struct. Biol. 2002; 12: 721-8.
10. Waxman DJ. P450 gene induction by structurally diverse xenochemicals: central role of nuclear receptors CAR, PXR, and PPAR. Arch. Biochem. Biophys. 1999; 369: 11-23.
11. Reddy JK. Nonalcoholic steatosis and steatohepatitis. III. Peroxisomal beta-oxidation, PPAR alpha, and steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 2001; 281: G1333-9.
12. Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. Implications for peroxisome proliferator-activated receptor alpha natural ligand metabolism. J. Biol. Chem. 1998; 273: 15 639-45.
13. Issemann I, Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990; 347: 645-50.
14. Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog. Horm. Res. 2001; 56: 239-63.
15. Torra IP, Chinetti G, Duval C, Fruchart JC, Staels B. Peroxisome proliferator-activated receptors: from transcriptional control to clinical practice. Curr. Opin. Lipidol. 2001; 12: 245-54.
16. Smith SA. Peroxisome proliferator-activated receptors and the regulation of mammalian lipid metabolism. Biochem. Soc. Trans. 2002; 30: 1086-90.
17. Kersten S. Peroxisome proliferator activated receptors and obesity. Eur. J. Pharmacol. 2002; 440: 223-34.
18. Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A pilot study of a thiazolidinedione, troglitazone, in nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2001; 96: 519-25.
19. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003; 38: 1008-17.
20. Everett L, Galli A, Crabb D. The role of hepatic peroxisome proliferator-activated receptors (PPARs) in health and disease. Liver 2000; 20: 191-9.
21. Lee CH, Chawla A, Urbiztondo N et al. Transcriptional repression of atherogenic inflammation: modulation by PPARdelta. Science 2003; 302: 453-7.
22. Wang YX, Lee CH, Tiep S et al. Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity. Cell 2003; 113: 159-70.
23. Moran TH, Katz LF, Plata Salaman CR, Schwartz GJ. Disordered food intake and obesity in rats lacking cholecystokinin A receptors. Am. J. Physiol. 1998; 274: R618-25.
24. Jia DM, Tabaru A, Akiyama T, Abe S, Otsuki M. Troglitazone prevents fatty changes of the liver in obese diabetic rats. J. Gastroenterol. Hepatol 2000; 15: 1183-91.
25. Sasagawa T, Ishii K, Hasuda K, Kubota M, Ota Y, Okita M. The effect of dietary polyunsaturated fatty acid on insulin sensitivity and lipid metabolism in Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Prostaglandins Leukot. Essent. Fatty Acids 2001; 64: 181-7.
26. Koteish A, Diehl AM. Animal models of steatosis. Semin. Liver Dis. 2001; 21: 89-104.
27. Okuno S, Kondo M, Yamasaki Y et al. Substitution of Dmo1 with normal alleles results in decreased manifestation of diabetes in OLETF rats. Diabetes Obes. Metab. 2002; 4: 309-18.
28. Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J. Biol. Chem. 2000; 275: 28 918-28.